OCEANIC-AF
2025
Oral Factor XIa Inhibitor Asundexian versus Apixaban in Patients With Atrial Fibrillation
In 14,810 patients with atrial fibrillation at high stroke risk, asundexian was inferior for prevention of stroke or systemic embolism compared with apixaban.
Result
Efficacy: Stroke or systemic embolismHR 3.79 (95% CI 2.46-5.83)
Safety: Major bleedingHR 0.32 (95% CI 0.18-0.55)
Below 1 favours asundexian, above 1 favours apixaban.
Event rates Asundexian 1.3% vs apixaban 0.4% (stroke or systemic embolism)
Also reported: Asundexian inferior to apixaban. Trial stopped early.
- Subtopic
- factor XIa inhibitor
- Design
- Phase 3 double-blind double-dummy active-controlled RCT, stopped early for inferiority
- Relevance
- Supporting: context rather than must-know.
- Source
- Piccini JP, et al. N Engl J Med. 2025;392(1):23-32.doi 10.1056/NEJMoa2407105
Discussion & critique
Possible underdosing of asundexian may have contributed to inferior efficacy, leaving the factor XIa hypothesis unresolved. Halted development of asundexian for stroke prevention in AF.